Life Science Company Addresses Antibiotic Resistance Problem

November 19, 2018

By The Life Science Report

Source: Streetwise Reports   11/18/2018

This firm’s proprietary technology provides an alternative to antibiotic use in livestock production.

Avivagen Inc. (VIV:TSX.V) announced in a news release it “strongly endorses” the World Health Organization’s (WHO) initiative to declare World Antibiotic Awareness Week Nov. 12 to 18, 2018, “which highlights the need for Avivagen’s products.”

Each year in the United States, Avivagen noted, 2 million-plus people become infected with antibiotic-resistant germs. These infections can be challenging and, in some cases, impossible to cure, often requiring long hospital stays and multiple physician visits. Consequently, at least 23,000 of Americans die as a result of the initial infection.


Get our Weekly Commitment of Traders Report: - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.




Get Our Free Metatrader 4 Indicators - Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter






According to the Centers for Disease Control, numerous medical procedures rely on antibiotics to prevent or combat infections. These encompass, for instance, surgeries such as joint replacements and organ transplants, therapies for life-threatening diseases like cancer, and treatments for chronic conditions including diabetes, rheumatoid arthritis and asthma.

Bacteria becoming drug resistant is primarily due to the excessive use of antibiotics in livestock to help them grow faster and withstand the stressful conditions in which they are raised, noted the release. Overuse leads germs to become unfazed by antibiotic effects, and the bacteria move into humans in that state. “This is the reason why the WHO and many other health organizations, countries and companies treat the removal of antibiotics as livestock growth promoters as a pressing global priority,” the release pointed out.

Avivagen views its proprietary OxC-beta technology as an alternative to antibiotic use in livestock and, therefore, a way to help lessen or eliminate that practice. OxC-beta, which improved the health of livestock and companion animals in Avivagen’s roughly 25 trials, is an ingredient of the company’s livestock feed products.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Avivagen. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.

( Companies Mentioned: VIV:TSX.V,
)